prostate cancer (nmCRPC)
Oncology · 2018–2022
7decisions
3medicines
6carried consumer input
20individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enzalutamide Treatment of non-metastatic castration-resistant prostate cancer (m0CRPC) in patients with PSA doubling time of 10 months or less. | Mar 2022 | Recommended with restriction | unclear |
| darolutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases (PSA doubling time ≤10 months). | Mar 2021 | Not recommended | input received Prostate Cancer Foundation · Medical Oncology Group |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined by prostate specific… | Nov 2021 | Recommended | input received Prostate Cancer Foundation · Medical Oncology Group |
| darolutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined by PSA doubling time ≤10… | Jul 2020 | Recommended with restriction | 3 individuals Geelong Prostate Support Group · Prostate Cancer Foundation · Medical Oncology Group |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined by a prostate-specific… | Nov 2020 | Not recommended | 2 individuals Prostate Cancer Foundation · Medical Oncology Group |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases (defined as PSA doubling time ≤10… | Jul 2019 | Not recommended | 6 individuals |
| apalutamide Treatment of patients with non-metastatic castration-resistant prostate cancer (m0CRPC) at high risk of distant metastases, defined as PSA doubling time ≤10… | Nov 2018 | Not recommended | 9 individuals |
Who spoke
Prostate Cancer Foundation · Medical Oncology Group · Geelong Prostate Support Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 6 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.